Nomura Asset Management Co. Ltd. Acquires 4,077 Shares of Illumina, Inc. (NASDAQ:ILMN)

Nomura Asset Management Co. Ltd. boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.8% during the third quarter, Holdings Channel reports. The fund owned 50,593 shares of the life sciences company’s stock after acquiring an additional 4,077 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Illumina were worth $6,598,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Primecap Management Co. CA increased its holdings in shares of Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares in the last quarter. Millennium Management LLC boosted its position in Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Illumina in the 2nd quarter valued at $77,628,000. Massachusetts Financial Services Co. MA raised its position in shares of Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after acquiring an additional 631,294 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. StockNews.com assumed coverage on Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. Stephens increased their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Piper Sandler reduced their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Barclays upped their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird raised their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $165.86.

Illumina Trading Down 0.8 %

Shares of NASDAQ:ILMN opened at $146.43 on Friday. The firm has a market cap of $23.22 billion, a price-to-earnings ratio of -14.70 and a beta of 1.11. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company’s fifty day simple moving average is $144.02 and its 200 day simple moving average is $127.89. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.